Stock Ratings / Health Care / SPRC / dividends

GNPX (47) OGEN (44) ARTL (41) PPBT (61) ⌘ Pro Terminal →

SciSparc Ltd. (SPRC) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does SPRC pay a dividend and is it safe?

SciSparc Ltd. (SPRC) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$0.71 -14.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.69

SciSparc Ltd. (SPRC) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SPRC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SPRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SciSparc Ltd. (NASDAQ: SPRC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $0.71 (-14.18% 1D, market cap $1.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SPRC ranks #236 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SPRC compare to GNPX and OGEN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRC carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GNPX (Genprex Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and OGEN (Oragenics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, SPRC leads on earnings multiple (N/A) while GNPX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SPRC?

▼

For SciSparc Ltd. (SPRC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #236 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.69 (-2.74%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY SPRC SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($41.0K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$4.47-62% Next Q

Q2 (-2Q)

Grade C$1.70-35.9% Next Q

Q3 (-1Q)

Grade C$1.09-34.9% Next Q

Current

Grade D+$0.71-0.5% Hist 90D α

Trajectory: C+ (63) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SPRC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, SPRC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.17) or 200D SMA ($5.59) invalidates the momentum regime and cuts Target Base ($0.70) toward Bear Floor ($0.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SPRC Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRC)

✓Walkthrough of SPRC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.90%▼ SUPPORT BREAKDOWN

2026-10-30O $0.68H $0.71L $0.60C $0.71VOL 348.9K

RES: $4.72SUP: $2.57SMA50: $4.17SMA200: $5.59

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPRC Butterfly Map → + Track SPRC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SPRC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPRC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRC)

Health Care Rank #236 of 1016 ⚔️ GNPX vs SPRC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPRC vs. GNPX, OGEN, ARTL, PPBT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SciSparc Ltd. (SPRC) ranks #236 by composite RQD confidence (55/100, grade D+) and #1010 by equity capitalization ($1.5M). Within this direct 5-issuer industry benchmark cohort, SPRC leads on earnings valuation at N/A trailing P/E, while GNPX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with SPRC at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPRC ACTIVE SciSparc Ltd.	D+	55/100	—	—	—	-14.18%	$1.5M	Benchmark Subject
GNPX Genprex Inc.	D	47/100	—	—	-35.0%	+1.49%	$1.7M	/gnpx-vs-sprc →
OGEN Oragenics Inc.	D	44/100	—	—	-35.0%	-1.53%	$1.7M	/ogen-vs-sprc →
ARTL Artelo Biosciences Inc.	D-	41/100	—	—	-35.0%	-0.86%	$1.3M	/artl-vs-sprc →
PPBT Purple Biotech Ltd.	C-	61/100	—	—	—	+13.86%	$1.8M	/ppbt-vs-sprc →

2. SPRC Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

SciSparc Ltd. (SPRC) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. SPRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SPRC compare to GNPX and OGEN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SPRC?

Where is SPRC trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRC last traded at $0.71 (-14.18% on volume of 593,035 shares), positioning the stock -82.97% below its 50-day simple moving average ($4.17) and -87.30% below its 200-day simple moving average ($5.59). Across its 52-week range of $0.60 to $30.63, SPRC sits at the 0.4% percentile with a 14-day RSI of 16.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.80).

SPRC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SPRC pay a dividend and is it safe?

SciSparc Ltd. (SPRC) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SPRC RQD Cockpit SPRC 12M Forecast SPRC Earnings & Move SPRC Dividends & DRIP SPRC Insiders & 13F SPRC Whale Options SPRC Profit Sankey SPRC News & Why